Allogene Therapeutics Q2 2024 GAAP EPS $(0.35), Inline
Portfolio Pulse from Benzinga Newsdesk
Allogene Therapeutics (NASDAQ:ALLO) reported a Q2 2024 GAAP EPS of $(0.35), which met the analyst consensus estimate.

August 07, 2024 | 9:38 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Allogene Therapeutics reported a Q2 2024 GAAP EPS of $(0.35), which was in line with analyst expectations. This neutral performance is unlikely to cause significant short-term price movements.
The reported earnings per share (EPS) met the analyst consensus estimate, indicating that the company's performance was as expected. This typically results in a neutral impact on the stock price as there are no surprises to drive significant buying or selling pressure.
CONFIDENCE 90
IMPORTANCE 50
RELEVANCE 100